Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 69353Y103 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Samsara BioCapital, L.P.
13G
|
9.9% |
9/15/2026
Event 9/2/2026
|
|
| Samsara BioCapital, L.P. | 5.0% | ||
| Samsara BioCapital GP, LLC | 5.0% | ||
| Samsara Opportunity Fund, L.P. | 5.0% | ||
| Samsara Opportunity Fund GP, LLC | 5.0% | ||
| Srinivas Akkaraju | 9.9% | ||
| Sio Capital Management, LLC 13G/A Amendment 4 | 4.9% |
7/28/2026
Event 6/30/2026
|
|
| ArrowMark Colorado Holdings LLC 13G/A Amendment 3 | 3.7% |
7/10/2026
Event 6/30/2026
|
|
|
Euclidean Capital LLC
13G/A
Amendment 4
|
4.9% |
5/15/2026
Event 3/31/2026
|
|
| Euclidean Capital LLC | 4.9% | ||
| Marilyn H. Simons | 4.9% | ||
| Ashvin B. Chhabra | 4.9% | ||
| Greenland NFP B Ltd. | 2.4% | ||
| Greenland NFP LLC | 0.1% | ||
| Greenland A LLC | 0.7% | ||
| Symmetry Group Ltd. | 0.5% | ||
| Sio Capital Management, LLC 13G/A Amendment 3 | 5.8% |
5/4/2026
Event 3/31/2026
|
|
|
Orbimed Advisors LLC
13D/A
Amendment 4
|
0% |
3/4/2026
Event 3/2/2026
|
|
| Orbimed Advisors LLC | 0% | ||
| Orbimed Capital GP V LLC | 0% | ||
| ArrowMark Colorado Holdings LLC 13G/A Amendment 2 | 5.8% |
2/17/2026
Event 12/31/2025
|
|
| BML Investment Partners, L.P. 13G/A Amendment 3 | 9.9% |
2/9/2026
Event 12/31/2025
|
|
| Sio Capital Management, LLC 13G/A Amendment 2 | 4.98% |
11/12/2025
Event 9/30/2025
|
|
|
Orbimed Advisors LLC
13D/A
Amendment 3
|
9.4% |
10/27/2025
Event 10/23/2025
|
|
| Orbimed Advisors LLC | 9.4% | ||
| Orbimed Capital GP V LLC | 9.4% | ||
|
Tang Capital Management LLC
13G
|
8.9% |
9/23/2025
Event 9/16/2025
|
|
| Tang Capital Management, LLC | 8.9% | ||
| Kevin Tang | 8.9% | ||
| Tang Capital Partners, LP | 5.0% | ||
| Tang Capital Partners International, LP | 3.9% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
PFM Health Sciences, LP
13G/A
Amendment 2
|
0% |
8/14/2025
Event 6/30/2025
|
|
| PFM Health Sciences, LP | 0% | ||
| PFM Health Sciences GP, LLC | 0% | ||
| Partner Asset Management, LLC | 0% | ||
| Brian D. Grossman | 0% | ||
| Sio Capital Management, LLC 13G/A Amendment 1 | 7.2% |
8/13/2025
Event 6/30/2025
|
|
|
PFM Health Sciences, LP
13G/A
Amendment 1
|
6.4% |
5/15/2025
Event 3/31/2025
|
|
| PFM Health Sciences, LP | 6.4% | ||
| PFM Health Sciences GP, LLC | 6.4% | ||
| Partner Asset Management, LLC | 6.4% | ||
| Brian D. Grossman | 6.4% | ||
| Sio Capital Management, LLC 13G | 7.2% |
4/8/2025
Event 3/31/2025
|
|
|
PFM Health Sciences, LP
13G
|
5.0% |
2/21/2025
Event 2/13/2025
|
|
| PFM Health Sciences, LP | 5.0% | ||
| PFM Health Sciences GP, LLC | 5.0% | ||
| Partner Asset Management, LLC | 5.0% | ||
| Brian D. Grossman | 5.0% | ||
| BML Investment Partners, L.P. 13G/A Amendment 2 | 6.7% |
2/14/2025
Event 12/31/2024
|
|
| BML Investment Partners, L.P. 13G/A Amendment 1 | 6.3% |
2/14/2025
Event 12/31/2024
|
|
| Sio Capital Management, LLC 13G | 6.9% |
2/10/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 67 | 34.6 M | $46.4 M |
| 2026 Q1 | 70 | 37.0 M | $45.8 M |
| 2025 Q4 | 66 | 37.6 M | $47.0 M |
| 2025 Q3 | 65 | 37.5 M | $52.5 M |
| 2025 Q2 | 56 | 35.3 M | $37.4 M |
| 2025 Q1 | 58 | 37.3 M | $40.7 M |
| 2024 Q4 | 73 | 39.0 M | $58.8 M |
| 2024 Q3 | 78 | 39.0 M | $58.2 M |
| 2024 Q2 | 98 | 40.8 M | $66.1 M |
| 2024 Q1 | 106 | 43.7 M | $74.3 M |
| 2023 Q4 | 108 | 51.6 M | $160 M |
| 2023 Q3 | 115 | 56.9 M | $349 M |
| 2023 Q2 | 110 | 51.8 M | $324 M |
| 2023 Q1 | 117 | 51.5 M | $246 M |
| 2022 Q4 | 124 | 57.9 M | $503 M |
| 2022 Q3 | 128 | 58.3 M | $694 M |
| 2022 Q2 | 117 | 61.1 M | $871 M |
| 2022 Q1 | 118 | 55.3 M | $1.15 B |
| 2021 Q4 | 109 | 47.6 M | $1.10 B |
| 2021 Q3 | 93 | 44.0 M | $1.31 B |
| 2021 Q2 | 89 | 43.0 M | $1.47 B |
| 2021 Q1 | 83 | 40.7 M | $1.34 B |
| 2020 Q4 | 74 | 38.2 M | $2.34 B |
| 2020 Q3 | 54 | 31.2 M | $1.10 B |